Katus M C, Szczepiorkowski Z M, Dumont L J, Dunbar N M
Department of Pathology, Transfusion Medicine Service, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Vox Sang. 2014 Aug;107(2):103-13. doi: 10.1111/vox.12146. Epub 2014 Mar 20.
Platelet components became routinely available to many institutions in the late 1960s and since then utilization has steadily increased. Platelets are produced by three principal methods and their manufacturing process is regulated by multiple agencies. As the field of platelet transfusion has evolved, a broad array of strategies to improve platelet safety has developed. This review will explore the evolution of modern platelet component therapy, highlight the various risks associated with platelet transfusion and describe risk reduction strategies that have been implemented to improve platelet transfusion safety. In closing, the reader will be briefly introduced to select investigational platelet and platelet-mimetic products that have the potential to enhance platelet transfusion safety in the near future.
血小板成分在20世纪60年代末开始在许多机构中常规供应，自那时起其使用量稳步增加。血小板通过三种主要方法生产，其制造过程由多个机构监管。随着血小板输血领域的发展，已经制定了一系列广泛的策略来提高血小板安全性。本综述将探讨现代血小板成分治疗的演变，强调与血小板输血相关的各种风险，并描述为提高血小板输血安全性而实施的风险降低策略。最后，将简要介绍一些有潜力在不久的将来提高血小板输血安全性的研究性血小板和血小板模拟产品。
